Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:LCAP NASDAQ:NAKA NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$33.63+0.5%$26.80$14.80▼$40.47$2.56B0.87975,405 shs1.11 million shsLCAPLionheart Acquisition Co. II$28.23+0.3%$10.38$8.94▼$11.70$521.02M0.08102,067 shs5,913 shsNAKAKindlyMD$4.80-40.6%$9.70$0.65▼$34.77$1.81B33.963.09 million shs5.78 million shsRXRXRecursion Pharmaceuticals$4.54-3.4%$5.37$3.79▼$12.36$1.97B0.9124.03 million shs15.76 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-0.65%+21.89%+34.69%+27.85%-11.76%LCAPLionheart Acquisition Co. II+0.52%+0.75%+2.40%+7.34%+18,061.29%NAKAKindlyMD+77.19%+74.51%-15.57%-55.94%+807,999,900.00%RXRXRecursion Pharmaceuticals+1.73%+0.86%-12.31%-12.96%-23.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$33.63+0.5%$26.80$14.80▼$40.47$2.56B0.87975,405 shs1.11 million shsLCAPLionheart Acquisition Co. II$28.23+0.3%$10.38$8.94▼$11.70$521.02M0.08102,067 shs5,913 shsNAKAKindlyMD$4.80-40.6%$9.70$0.65▼$34.77$1.81B33.963.09 million shs5.78 million shsRXRXRecursion Pharmaceuticals$4.54-3.4%$5.37$3.79▼$12.36$1.97B0.9124.03 million shs15.76 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-0.65%+21.89%+34.69%+27.85%-11.76%LCAPLionheart Acquisition Co. II+0.52%+0.75%+2.40%+7.34%+18,061.29%NAKAKindlyMD+77.19%+74.51%-15.57%-55.94%+807,999,900.00%RXRXRecursion Pharmaceuticals+1.73%+0.86%-12.31%-12.96%-23.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.92Moderate Buy$53.9162.12% UpsideLCAPLionheart Acquisition Co. II 0.00N/AN/AN/ANAKAKindlyMD 3.00Buy$8.0061.94% UpsideRXRXRecursion Pharmaceuticals 2.40Hold$7.2558.12% UpsideCurrent Analyst Ratings BreakdownLatest LCAP, NAKA, CGON, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025CGONCG OncologyJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.009/8/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$75.009/5/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/3/2025NAKAKindlyMDMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/1/2025CGONCG OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/18/2025CGONCG OncologyPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$55.007/16/2025CGONCG OncologyRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$68.00 ➝ $53.007/10/2025CGONCG OncologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$40.007/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.007/3/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$5.006/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$52.00 ➝ $56.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$551K4,601.59N/AN/A$9.63 per share3.45LCAPLionheart Acquisition Co. IIN/AN/A$1.37 per share20.64($2.85) per shareN/ANAKAKindlyMD$2.72M683.10N/AN/A$0.43 per share11.49RXRXRecursion Pharmaceuticals$58.84M33.83N/AN/A$2.61 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)LCAPLionheart Acquisition Co. II$3.21MN/A0.00∞N/AN/A-44.30%1.39%N/ANAKAKindlyMD-$3.62M-$0.86N/A∞N/A-244.00%-131.09%-106.04%N/ARXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest LCAP, NAKA, CGON, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A8/5/2025Q2 2025NAKAKindlyMDN/A-$0.34N/A-$0.35N/A$0.41 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/ALCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A22.1522.15LCAPLionheart Acquisition Co. IIN/A0.050.05NAKAKindlyMDN/A13.0013.00RXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%LCAPLionheart Acquisition Co. IIN/ANAKAKindlyMDN/ARXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipCGONCG OncologyN/ALCAPLionheart Acquisition Co. II19.40%NAKAKindlyMD40.79%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6176.25 millionN/AOptionableLCAPLionheart Acquisition Co. II318.45 million14.87 millionNot OptionableNAKAKindlyMDN/A376.12 million222.70 millionN/ARXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableLCAP, NAKA, CGON, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Advisors Asset Management Inc.September 10 at 3:45 AM | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8 at 9:01 PM | seekingalpha.comRussell Investments Group Ltd. Has $206,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 4, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comJump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRXAugust 29, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 AcquisitionAugust 28, 2025 | insidermonkey.comRecursion to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLCAugust 25, 2025 | marketbeat.comNeedham Maintains Buy Rating on Recursion (RXRX)August 24, 2025 | msn.comThe Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to ExplodeAugust 23, 2025 | fool.comRecursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.August 23, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Caught a Cold This WeekAugust 22, 2025 | fool.comRecursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025August 22, 2025 | finance.yahoo.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of StockAugust 21, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of SharesAugust 21, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's WhyAugust 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 SharesAugust 20, 2025 | insidertrades.comEverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comLPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comRecursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment DataAugust 19, 2025 | seekingalpha.comLiontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)August 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCAP, NAKA, CGON, and RXRX Company DescriptionsCG Oncology NASDAQ:CGON$33.63 +0.16 (+0.48%) Closing price 04:00 PM EasternExtended Trading$33.66 +0.03 (+0.09%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Lionheart Acquisition Co. II NASDAQ:LCAPLionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.KindlyMD NASDAQ:NAKA$4.80 -3.28 (-40.59%) As of 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.Recursion Pharmaceuticals NASDAQ:RXRX$4.54 -0.16 (-3.40%) Closing price 04:00 PM EasternExtended Trading$4.59 +0.05 (+1.10%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
